Arcutis Biotherapeutics (ARQT) Superinvestor holders
19 of the superinvestors we track hold Arcutis Biotherapeutics (ARQT) in their latest 13F filings, $343M in total.
Summary
The largest holder is Jennison Associates, with $111M, 0.1% of the portfolio.
In their latest quarter: 5 opened a new position, 5 added, 7 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Jennison Associates | Trimmed | 4,219,058 | $111M | 0.1% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Added | 3,949,609 | $104M | 0.1% | Q2 2026 |
| Ron Baron Baron Capital (BAMCO) |
Added | 1,253,120 | $33M | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Trimmed | 974,534 | $26M | 0.0% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Added | 663,877 | $17M | 0.0% | Q2 2026 |
| Paul Marshall Marshall Wace |
Trimmed | 446,866 | $12M | 0.0% | Q2 2026 |
| Steve Cohen Point72 Asset Management |
Trimmed | 362,449 | $10M | 0.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | 330,324 | $9M | 0.0% | Q2 2026 |
| Brandon Haley Holocene Advisors |
New position | 163,732 | $4M | 0.0% | Q2 2026 |
| David Vogel Voloridge Investment Management |
Trimmed | 157,429 | $4M | 0.0% | Q2 2026 |
| Peter Muller PDT Partners |
Held | 155,075 | $4M | 0.2% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp |
New position | 131,914 | $3M | 0.0% | Q2 2026 |
| Man Group Man Group plc |
Added | 94,272 | $2M | 0.0% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Trimmed | 58,399 | $2M | 0.0% | Q2 2026 |
| Alec Litowitz Magnetar Capital |
New position | 56,082 | $1M | 0.0% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
New position | 19,032 | $499,019 | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
Added | 16,192 | $427,000 | 0.0% | Q3 2026 |
| Ken Tropin Graham Capital Management |
New position | 10,022 | $262,777 | 0.0% | Q2 2026 |
| Didric Cederholm Lion Point Capital |
Held | 5,250 | $137,655 | 0.7% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 19 |
| Q1 2026 | 15 |
| Q4 2025 | 17 |
| Q3 2025 | 14 |
| Q2 2025 | 12 |
| Q1 2025 | 17 |
| Q4 2024 | 13 |
| Q3 2024 | 16 |
Questions about Arcutis Biotherapeutics
Which superinvestors own Arcutis Biotherapeutics?
19 of the superinvestors we track hold Arcutis Biotherapeutics (ARQT) in their latest 13F filings, $343M in total. Jennison Associates, David Shaw, Ron Baron, Ensign Peak, Two Sigma, Paul Marshall.
Who is the largest superinvestor holder of ARQT?
The largest holder is Jennison Associates, with $111M, 0.1% of the portfolio.
From Arcutis Biotherapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.